Aytu BioPharma Inc (LTS:0A8M)
$ 1.64 0.05 (3.14%) Market Cap: 9.90 Mil Enterprise Value: 6.35 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 40/100

Aytu BioScience Inc to Acquire Neos Therapeutics Inc- M&A Call Transcript

Dec 10, 2020 / 01:30PM GMT
Operator

Good morning and thank you for joining us for today's conference call discussing Aytu Biosciences planned acquisition of Neo Therapeutics. With me this morning are Aytu Bioscience Chairman and Chief Executive Officer, Josh Disbrow; and Neo Therapeutics' Chief Executive Officer, Jerry McLaughlin.

Aytu Bioscience issued a press release earlier this morning with details of Aytu Biosciences planned acquisition of Neo Therapeutics. A copy of that press release is available on the news page of Aytu website at aytubio.com.

I would like to remind everybody that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and the conference ID provided in the press release. In addition, a webcast will be accessible live and archived on Aytu's website within the Investor Relations section, under Events and Presentations at aytubio.com.

I'd also like to call your attention to the customary safe harbor disclosure regarding forward-looking information. Today's conference call may be -- may include forward-looking statements within the meanings of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot